Mergers & acquisitions
Bayer is taking multiple shots at Parkinson’s disease with BlueRock dosing its first patient in a Phase I stem cell study, and AskBio is assessing a gene therapy treatment for the disease.
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
It didn’t take too long before a lawsuit was filed over Bristol Myers Squibb’s failure to meet a deadline for a $9 Contingent Value Rights agreement tied to the company’s merger with Celgene.
Bayer will nab exclusive rights to a differentiated alpha radionuclide, actinium-225 investigational compound, and a small molecule targeting prostate-specific membrane antigen.
venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.
Venture capitalist Chamath Palihapitiya is raising $800 million to finance four more special purpose acquisition companies that will be focused on taking biotech companies public.
MorphoSys Pharma is acquiring Constellation Pharmaceuticals for about $1.7 billion. Here’s everything you need to know about this billion dollars deal.
The company, which isn’t expected to enter the clinic until possibly in 2022, is working to make cell therapies work in solid tumors.
The UK’s Competition and Markets Authority (CMA) will determine if the deal is anti-competitive.
Less than two weeks after Ginkgo Bioworks announced a merger with SPAC Soaring Eagle Acquisition Corp., it announced a collaboration partnership with Biogen.
PRESS RELEASES